Table 2.
Treatments, syndromes, and outcomes of patients who received CAR T-cell therapy
| Characteristic | All patients (n = 40) (%) | Complete case patients (n = 33) (%) |
|---|---|---|
| Type of CAR T received, n (%) | ||
| axicabtagene-ciloleucel (Yescarta) | 24 (60) | 21 (64) |
| brexucabtagene autoleucel (Tecartus) | 8 (20) | 6 (18) |
| tisagenlecleucel (Kymriah) | 5 (13) | 3 (9) |
| Experimental anti B-cell maturation antigen (anti-BCMA) therapies | 3 (7.5) | 3 (9) |
| Pre-treatment left ventricular ejection fraction (LVEF) | ||
| Normal LVEF ≥ 50%, n (%) | 36 (90) | 30 (91) |
| Moderately reduced LVEF 30–45%, n (%) | 3 (7.5) | 2 (6) |
| No pre-treatment echocardiogram | 1 (2.5) | 1 (3) |
| Post-treatment LVEF | ||
| Normal LVEF ≥ 50%, n (%) | 10 (25) | 9 (27) |
| Moderately reduced LVEF 30–45%, n (%) | 0 (0) | 0 (0) |
| No post-treatment echocardiogram | 30 (75) | 24 (73) |
| Maximum grade of cytokine release syndrome (CRS)*, n (%) | ||
| Grade 2 | 17 (43) | 15 (45) |
| Grade 1 | 14 (35) | 11 (33) |
| No CRS | 9 (23) | 7 (21) |
| Immune effector cell-associated neurotoxicity syndrome | 19 (48) | 16 (48) |
| All-cause mortality at 1 year | 7 (18) | 5 (15) |
| All-cause mortality at median 588 days of follow-up** | 11 (28) | 8 (24) |
*
CRS treatment statistics: Among the 17 patients who had CRS of maximum grade 2, 10/17 received corticosteroids, 10/17 received intravenous fluids, and 13/17 received tocilizumab. Among 13 patients who had CRS of maximum grade 1 or no CRS, 5/23 received corticosteroids, 2/23 received intravenous fluids, and 8/23 received tocilizumab.
**
Cause of death was progression of cancer in 6/11; or indiscernible from chart review due to use of outside hospitals or hospice agencies in 5/11.